Skip to main content
. 2016 Aug 10;8(25):40169–40180. doi: 10.18632/oncotarget.11174

Figure 3. MiR-199b sensitizes CRC cells to oxaliplatin and 5-FU treatments.

Figure 3

MTS assays showing the effect of miR-199b in the sensitivity to oxaliplatin (A) or 5-FU (B) in SW480 and HT-29 cells; Data represented are mean of three independent experiments ± SD. *P < 0.05; **P < 0.01.